High-Throughput
Find expert resources here on the technical and strategic foundations of parallel candidate evaluation and lead selection. evitria’s specialized High-Throughput antibody expression service utilizes a proprietary CHO transient platform to provide manufacturing-relevant data from the very first screening run. Learn more about our high-throughput antibody production service to de-risk your discovery pipeline with 15 years of Swiss expertise.
Articles about High-Throughput (19)
-
What is the Typical Turnaround Time for HTP Antibody Production?
evitria’s HTP Antibody Production Service delivers purified, analytics-confirmed material within a 4-week cycle from sequence approval. Learn what factors influence turnaround time and how to plan your screening campaign effectively.
-
Developability-by-Design: The 5 Readouts to Check Before Picking Winners
Identifying a high-affinity binder is only the first hurdle in antibody discovery. Developability-by-Design integrates five key biophysical readouts into the selection process to ensure only manufacturable candidates advance.
-
Why HTP Screening Results Sometimes Fail to Translate to Manufacturing
Top-tier HTP screening leads frequently fail to translate to manufacturing due to host system incompatibilities and production artefacts. This article examines the root causes and how to close the translation gap.
-
High-Throughput Screening (HTS): Moving from Production to Data
High-Throughput Screening bridges antibody production and data generation, transforming large panels of expressed proteins into actionable biological insights. Understanding this workflow is essential for designing a productive discovery campaign.
-
Benefits of High-Throughput Antibody Expression in Early-Stage Discovery
High-Throughput Antibody Expression accelerates early-stage discovery by translating digital sequence libraries into physical proteins at unprecedented speed. Discover how HTP production compresses the path from sequence to validated lead.
-
The Top 5 Problems with High-Throughput Antibody Expression and How to Avoid Them
High-throughput antibody expression exposes technical liabilities that remain invisible until they cause failure at scale. This article identifies the five most common problems and how to proactively avoid them.
-
How to Design an HTP Screening Campaign for Reliable Lead Comparability
Reliable lead comparability in an HTP screening campaign depends on high-fidelity production and a consistent host system. This guide outlines how to structure your campaign to generate decision-grade data.
-
Primary vs. Secondary Screening: Why CHO-Based Material is Essential
The host system used during primary screening determines whether lead candidates are genuinely ready for development. CHO-based material ensures data generated at the screening stage translates directly to manufacturing.
-
Hidden Costs in HTP: Why “Cheap” HEK293 Material Costs Millions Later
Choosing HEK293 cells based on lower upfront cost introduces hidden downstream risks that can cost millions in failed preclinical development. Understanding the true economics of host system selection is critical.
-
Batch Effects in HTP: Identifying Sources and Strategies for Reduction
Batch effects are systematic, non-biological sources of variation that distort HTP screening results. Identifying their root causes and applying targeted reduction strategies is essential for reliable lead selection.
-
Transient vs. Stable Expression in HTP: When to Make the Switch
Learn when to switch from transient to stable expression in HTP antibody programs. Three technical triggers and a CHO-based strategy that de-risks the move.
-
Garbage In, Garbage Out: Why AI Antibody Discovery Needs Data Integrity
AI antibody discovery models are only as reliable as the data they train on. Learn why standardized CHO-native HTP production is the foundation of valid AI predictions.
